How to use this tool
How to use this tool
InvestorGuide Stock Analysis
Will Shareholders Agree to Sell Genentech?
Excerpt from the InvestorGuide.com Stock of the Day on 2/2/2009
About six months ago, Swiss drugmaker Roche offered to buy out all of Genentech's remaining stock in a deal worth $44 billion. This equals about $89 per share. This represented a 9 percent premium at the time. The board of directors evaluated this offer and about a month later, rejected the bid saying the price significantly undervalued the company's worth and growth potential. Little else has occurred since, but on Friday, Roche took the deal directly to shareholders asking to buy their equity for $86.50 per share. The US biotech firm advised shareholders not to take action so it can review its current position and prepare a formal response. Investors and analysts expect an announcement within two weeks. By the end of Friday, Genentech's stock closed at $81.50, indicating investors are complying. Having been rejected once by the company, will Roche be rejected a second time by shareholders? More >
Excerpt from the InvestorGuide.com Stock of the Day on 2/2/2009
About six months ago, Swiss drugmaker Roche offered to buy out all of Genentech's remaining stock in a deal worth $44 billion. This equals about $89 per share. This represented a 9 percent premium at the time. The board of directors evaluated this offer and about a month later, rejected the bid saying the price significantly undervalued the company's worth and growth potential. Little else has occurred since, but on Friday, Roche took the deal directly to shareholders asking to buy their equity for $86.50 per share. The US biotech firm advised shareholders not to take action so it can review its current position and prepare a formal response. Investors and analysts expect an announcement within two weeks. By the end of Friday, Genentech's stock closed at $81.50, indicating investors are complying. Having been rejected once by the company, will Roche be rejected a second time by shareholders? More >
Qiagen N.V. (QGEN) Upgrades
Date
Analyst
Old Rating
New Rating
No upgrades listed for QGEN at this time.
Qiagen N.V. (QGEN) Downgrades
Date
Analyst
Old Rating
New Rating
07/10/2009
UBS
Buy
Neutral
02/12/2009
Credit Suisse
Outperform
Neutral
Qiagen N.V. (QGEN) New Coverage
Date
Analyst
Rating
10/26/2009
Cowen & Co
Outperform
10/07/2009
Barclays
Overweight
03/03/2009
Jefferies & Co
Buy
10/10/2007
Piper Jaffray & Co.
Outperform
Special Offers
| Buy Qiagen N.V. for just $4 www.sharebuilder.com |
| What is Morningstar's rating for Qiagen N.V.? www.morningstar.com |
| Learn to spot opportunities in any market with a Risk-Free* 30-day trial from Investools. www.investools.com |
| Lightspeed Trading. Get the unfair advantage of a platform built for traders, by traders. www.lightspeed.com |
| Download a free Options Fundamentals Podcast, from The Options Industry Council. OptionsEducation.org |
QGEN Links
Guru Analysis:
MSN Money | Morningstar | Stock Consultant
Analyst Opinions:
Reuters | SmartMoney | MarketWatch | Nasdaq | BarChart | Schaeffers | CNN Money | TheStreet
Blogs:
SocialPicks | Topix.net | SeekingAlpha | Technorati | Ask.com
Message Boards:
ClearStation | RagingBull | Yahoo | Investopedia | FreeRealTime | StockHouse Trading Offers:
Buy QGEN for just $4
MSN Money | Morningstar | Stock Consultant
Analyst Opinions:
Reuters | SmartMoney | MarketWatch | Nasdaq | BarChart | Schaeffers | CNN Money | TheStreet
Blogs:
SocialPicks | Topix.net | SeekingAlpha | Technorati | Ask.com
Message Boards:
ClearStation | RagingBull | Yahoo | Investopedia | FreeRealTime | StockHouse Trading Offers:
Buy QGEN for just $4
